Targeting APRIL in the treatment of glomerular diseases

IF 14.8 1区 医学 Q1 UROLOGY & NEPHROLOGY Kidney international Pub Date : 2024-09-07 DOI:10.1016/j.kint.2024.08.012
Chee Kay Cheung , Jonathan Barratt , Richard Lafayette , Adrian Liew , Yusuke Suzuki , Vladimír Tesař , Hernán Trimarchi , Muh Geot Wong , Hong Zhang , Dana V. Rizk
{"title":"Targeting APRIL in the treatment of glomerular diseases","authors":"Chee Kay Cheung ,&nbsp;Jonathan Barratt ,&nbsp;Richard Lafayette ,&nbsp;Adrian Liew ,&nbsp;Yusuke Suzuki ,&nbsp;Vladimír Tesař ,&nbsp;Hernán Trimarchi ,&nbsp;Muh Geot Wong ,&nbsp;Hong Zhang ,&nbsp;Dana V. Rizk","doi":"10.1016/j.kint.2024.08.012","DOIUrl":null,"url":null,"abstract":"<div><div>A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell–depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 806-818"},"PeriodicalIF":14.8000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S008525382400574X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell–depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
靶向 APRIL 治疗肾小球疾病。
增殖诱导配体(APRIL)是肿瘤坏死因子(TNF)超家族细胞因子的一个重要成员,在 B 细胞存活、增殖和免疫球蛋白类别转换中起着核心作用。最近,由于 APRIL 和相关细胞因子 B 细胞活化因子(BAFF)在上述过程中的重要作用,人们越来越关注它们在几种肾小球疾病中的作用。治疗性抑制 APRIL 代表了一种具有潜在吸引力的免疫调节方法,它可以消除自身免疫性疾病中有害的宿主免疫反应,同时保持体液免疫的其他重要功能完好无损,如记忆 B 细胞功能和疫苗接种反应,与 B 细胞耗竭策略形成鲜明对比。在这篇综述中,我们描述了APRIL在B细胞发育中的生理作用及其与肾小球疾病的相关性,并概述了研究APRIL抑制剂的新临床试验数据,重点是IgA肾病,APRIL抑制剂的临床开发正处于最后期阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Kidney international
Kidney international 医学-泌尿学与肾脏学
CiteScore
23.30
自引率
3.10%
发文量
490
审稿时长
3-6 weeks
期刊介绍: Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.
期刊最新文献
Semaglutide and kidney function: direct kidney protection or an artifact? The critical role of endoplasmic reticulum stress and the stimulator of interferon genes (STING) pathway in kidney fibrosis. PI3Kα in the pathogenesis and treatment of lupus nephritis. Translational Science Advancing Anti-Inflammatory Therapies - Leveraging Glucocorticoid Pathways for Novel Treatments. A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1